Ann Yellowlees

1.2k total citations · 1 hit paper
30 papers, 927 citations indexed

About

Ann Yellowlees is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ann Yellowlees has authored 30 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Ann Yellowlees's work include Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (5 papers) and Statistical Methods in Clinical Trials (4 papers). Ann Yellowlees is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Breast Cancer Treatment Studies (5 papers) and Statistical Methods in Clinical Trials (4 papers). Ann Yellowlees collaborates with scholars based in United Kingdom, United States and Netherlands. Ann Yellowlees's co-authors include Julian Howell, Stefan Arver, Ignacio Moncada, Kevin S. Channer, Maurizio Volterrani, Irène Buvat, E.J.H. Meuleman, T. Hugh Jones, Hermann M. Behre and Antonio Martín Morales and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes Care and JNCI Journal of the National Cancer Institute.

In The Last Decade

Ann Yellowlees

30 papers receiving 891 citations

Hit Papers

Testosterone Replacement in Hypogonadal Men With Type 2 D... 2011 2026 2016 2021 2011 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)
    2011 426 citations T. Hugh Jones, Stefan Arver et al. Diabetes Care profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann Yellowlees United Kingdom 11 410 275 249 184 167 30 927
Louis A. Matej United States 9 564 1.4× 84 0.3× 107 0.4× 53 0.3× 437 2.6× 12 1.1k
Bruno Madeo Italy 19 407 1.0× 162 0.6× 40 0.2× 56 0.3× 172 1.0× 56 1.0k
Juuso Mäkinen Finland 10 349 0.9× 44 0.2× 92 0.4× 24 0.1× 112 0.7× 15 581
Corrales Hernández Jj Spain 16 612 1.5× 25 0.1× 133 0.5× 22 0.1× 218 1.3× 64 1.0k
Katherine Rowland Canada 12 222 0.5× 153 0.6× 18 0.1× 36 0.2× 105 0.6× 16 829
Sam S. Miller United States 11 433 1.1× 147 0.5× 30 0.1× 44 0.2× 109 0.7× 12 900
Thiago Gagliano‐Jucá United States 12 233 0.6× 27 0.1× 82 0.3× 17 0.1× 60 0.4× 33 458
Şazi İmamoğlu Türkiye 16 421 1.0× 68 0.2× 38 0.2× 30 0.2× 742 4.4× 48 1.5k
Micheline C. Chu United States 14 219 0.5× 76 0.3× 42 0.2× 58 0.3× 649 3.9× 21 1.3k
H. Schuster Germany 20 456 1.1× 31 0.1× 30 0.1× 231 1.3× 44 0.3× 67 1.3k

Countries citing papers authored by Ann Yellowlees

Since Specialization
Citations

This map shows the geographic impact of Ann Yellowlees's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Yellowlees with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Yellowlees more than expected).

Fields of papers citing papers by Ann Yellowlees

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Yellowlees. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Yellowlees. The network helps show where Ann Yellowlees may publish in the future.

Co-authorship network of co-authors of Ann Yellowlees

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Yellowlees. A scholar is included among the top collaborators of Ann Yellowlees based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Yellowlees. Ann Yellowlees is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Finch, Courtney L., William E. Dowling, Ramon Roozendaal, et al.. (2022). Bridging Animal and Human Data in Pursuit of Vaccine Licensure. Vaccines. 10(9). 1384–1384. 8 indexed citations
2.
Leonard, Robert, Ann Yellowlees, Janine Mansi, Lesley Fallowfield, & Valerie Jenkins. (2020). The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial. The Breast. 52. 122–131. 4 indexed citations
3.
Leonard, Robert, Douglas Adamson, Gianfilippo Bertelli, et al.. (2017). GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Annals of Oncology. 28(8). 1811–1816. 108 indexed citations
4.
Fleetwood, Kelly, Julie Glanville, Rachael McCool, et al.. (2016). A Review of the Use of Network Meta-Analysis In Nice Single Technology Appraisals. Value in Health. 19(7). A348–A348. 5 indexed citations
5.
Bursa, Francis, et al.. (2016). Estimation of Relative Potency from Bioassay Data that Include Values below the Limit of Quantitation. BioScience. 66(11). 983–989. 1 indexed citations
6.
Gibson, Peter G., Peter J. Whorwell, John Kellow, et al.. (2016). Systematic review and meta-analysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population. Therapeutic Advances in Gastroenterology. 10(1). 74–88. 20 indexed citations
7.
Fleetwood, Kelly, et al.. (2015). Alternatives To Winbugs for Network Meta–Analysis. Value in Health. 18(7). A720–A720. 16 indexed citations
8.
Fleetwood, Kelly, Francis Bursa, & Ann Yellowlees. (2015). Parallelism in Practice: Approaches to Parallelism in Bioassays. PDA Journal of Pharmaceutical Science and Technology. 69(2). 248–263. 10 indexed citations
9.
Yellowlees, Ann, et al.. (2015). Estimating vaccine efficacy using animal efficacy data. European Journal of Pharmacology. 759. 63–68. 3 indexed citations
10.
11.
Perry, Rachel, et al.. (2014). Estimating Survival Data from Published Kaplan-Meier Curves: a Comparison of Methods. Value in Health. 17(7). A326–A326. 5 indexed citations
12.
Craig, Joyce, James Mahon, Ann Yellowlees, et al.. (2014). Epithelium-Off Photochemical Corneal Collagen Cross-Linkage Using Riboflavin and Ultraviolet A for Keratoconus and Keratectasia: A Systematic Review and Meta-Analysis. The Ocular Surface. 12(3). 202–214. 29 indexed citations
13.
Taylor, Matthew, et al.. (2013). The Use of Data from Published Kaplan-Meier Survival Curves in NICE HTAs. Value in Health. 16(7). A594–A594. 2 indexed citations
14.
Berry, Scott, Charles F. Barish, Raj Bhandari, et al.. (2013). Nitroglycerin 0.4% ointment vs placebo in the treatment of pain resulting from chronic anal fissure: a randomized, double-blind, placebo-controlled study. BMC Gastroenterology. 13(1). 106–106. 20 indexed citations
15.
Price, Allan, Ann Yellowlees, Catriona Keerie, et al.. (2012). Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer. Lung Cancer. 77(3). 532–536. 8 indexed citations
16.
Wade, Alan, G. Crawford, & Ann Yellowlees. (2011). Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study. BMC Psychiatry. 11(1). 42–42. 18 indexed citations
17.
Jones, T. Hugh, Stefan Arver, Hermann M. Behre, et al.. (2011). Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study). Diabetes Care. 34(4). 828–837. 426 indexed citations breakdown →
18.
19.
Léonard, Renaud, M. Lind, C.J. Twelves, et al.. (2004). Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial. JNCI Journal of the National Cancer Institute. 96(14). 1076–1083. 39 indexed citations
20.
Evans, T.R. Jeffry, Ann Yellowlees, Helena Earl, et al.. (2004). Phase III randomised trial of doxorubicin (A) and docetaxel (D) versus A and cyclophosphamide (C) as primary medical therapy (PMT) in women with breast cancer. Journal of Clinical Oncology. 22(14_suppl). 521–521. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Louis A. Matej Breakdown of academic impact, for papers by Bruno Madeo Breakdown of academic impact, for papers by Juuso Mäkinen Breakdown of academic impact, for papers by Corrales Hernández Jj Breakdown of academic impact, for papers by Katherine Rowland Breakdown of academic impact, for papers by Sam S. Miller Breakdown of academic impact, for papers by Thiago Gagliano‐Jucá Breakdown of academic impact, for papers by Şazi İmamoğlu Breakdown of academic impact, for papers by Micheline C. Chu Breakdown of academic impact, for papers by H. Schuster
Rankless by CCL
2026